Natera
307 articles about Natera
-
Medicare Extends Coverage of Natera's Signatera™ MRD Test to Muscle Invasive Bladder Cancer
7/18/2022
Natera, Inc. (NASDAQ: NTRA), today announced that it has received written confirmation from the CMS Molecular Diagnostics Services Program (MolDX) that the Signatera molecular residual disease (MRD) test has met coverage requirements for patients with muscle invasive bladder cancer (MIBC), effective April 19, 2022.
-
Natera Selected for UnitedHealthcare's Preferred Laboratory Network
7/14/2022
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced it has been selected to participate in UnitedHealthcare's Preferred Laboratory Network (PLN).
-
Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study
6/29/2022
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of a manuscript in a leading journal in the organ transplant space, Transplantation, validating the performance of a novel two-threshold algorithm for its Prospera™ test for the assessment of transplant rejection.
-
Natera Showcases Leadership in Transplantation at ATC 2022 with New Data on its Prospera and Renasight Tests
6/8/2022
Includes oral presentation on Prospera test's two-threshold algorithm, showing the combination of donor quantity and donor fraction outperforms donor fraction alone.
-
Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at the 2022 ASCO Annual Meeting
5/31/2022
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the 2022 ASCO® Annual Meeting taking place June 3 – 7, 2022.
-
Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology
5/24/2022
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the appointment of Minetta Liu , M.D., as its new chief medical officer (CMO) of oncology.
-
Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additional Investment in Natera
5/16/2022
Natera, Inc. announced that Matthew Rabinowitz, co-founder and Executive Chairman of Natera, together with his family's trust, have recently acquired a total of 470,000 shares of Natera stock through the purchase of additional shares on the open market and from the exercise of stock options.
-
Natera Reports First Quarter 2022 Financial Results
5/5/2022
Natera, Inc., a global leader in cell-free DNA testing, reported financial results for the first quarter ended March 31, 2022 and provided an update on recent business progress and financial outlook.
-
Natera Announces First Quarter 2022 Earnings Conference Call
5/2/2022
Natera, Inc. today announced that it will release results for its first quarter ended March 31, 2022, after the market close on May 5, 2022.
-
Arguments regarding the Purdue Pharma opioid settlement continue to be heard in court, Natera battles a class-action lawsuit, Walgreens is involved in a public nuisance suit and more.
-
Natera Announces Definitive Study to Evaluate the Clinical Utility of Renasight in the Diagnosis and Management of Chronic Kidney Disease (CKD)
4/26/2022
Natera, Inc. today announced the RenaCARE (Renasight Clinical Application, Review and Evaluation) study - a real world, prospective, multi-center clinical study to assess the clinical utility of the Renasight™ genetic testing panel.
-
Large Real-World Study with Renasight Genetic Test Highlights High Diagnostic Yield for Patients with Chronic Kidney Disease
4/19/2022
Natera, Inc. announced the results of a large, real-world study 1 demonstrating a high yield rate for positive genetic findings with its Renasight™ test in patients with chronic kidney disease (CKD).
-
Multi-Site Clinical Validation of Prospera Heart Test Demonstrates Outstanding Performance in Assessing Heart Transplant Rejection
4/13/2022
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived cell-free DNA (dd-cfDNA) test for the assessment of acute rejection in heart transplant patients, Prospera™ Heart, has been published in the Journal of Heart and Lung Transplantation - a leading journal with the highest impact factor in the transplantation sector.
-
Natera to Present Data from the BEATRICE and I-SPY2 Trials in Early-Stage TNBC and HR+/HER2- Breast Cancer at the 2022 AACR Annual Meeting
4/11/2022
Natera, Inc. today announced that it will present new data relating to its personalized and tumor-informed molecular residual disease (MRD) test, Signatera™, at the annual meeting of the American Association for Cancer Research taking place April 8 – 13, 2022.
-
Natera Publishes VALID Study Results for Prospera Lung dd-cfDNA Transplant Rejection Assessment Test
4/7/2022
Natera, Inc. today announced the publication of the VALID study, showcasing its Prospera™ Lung donor-derived cell-free DNA (dd-cfDNA) test in assessing rejection and allograft injury in lung transplant patients.
-
Natera Adds to Organ Health Medical Affairs Leadership Team
4/6/2022
Sangeeta Bhorade , M.D., appointed as head of organ health medical affairs.
-
Natera Announces Publication Highlighting Importance of Testing Total cfDNA when Monitoring Kidney Transplant Patients with COVID-19 Infection
4/1/2022
Natera, Inc. announced the results of a study 1 to examine both total and donor-derived cell-free DNA (dd-cfDNA) in kidney transplant recipients hospitalized with COVID-19 using its Prospera™ test to assess disease severity and risk of rejection.
-
Natera Listed as One of World's Most Innovative Health Companies by Fast Company
3/28/2022
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, has been named to Fast Company's annual list of the World's Most Innovative Companies for 2022.
-
UPDATE -- CareDx Wins $44.9M in Damages in False Advertising Trial Against Natera; Natera Intentionally Deceived Transplant Community
3/23/2022
CareDx, Inc. today announced that the Company won its false advertising case against Natera.
-
New Data in Simultaneous Pancreas-Kidney Transplantation Further Demonstrates the Value of Prospera dd-cfDNA Technology
3/22/2022
Natera, Inc. today announced that a study 1 reporting on the performance of donor-derived cell-free DNA (dd-cfDNA) testing using the Prospera™ technology for the assessment of pancreas graft rejection in simultaneous pancreas-kidney (SPK) transplantation has been published in Transplantation, the official Journal of The Transplantation Society.